{"name": "Astex",
 "permalink": "astex",
 "crunchbase_url": "http://www.crunchbase.com/company/astex",
 "homepage_url": "http://www.astex-therapeutics.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@astex-therapeutics.com",
 "phone_number": "+44 (0)1223 226200",
 "description": "",
 "created_at": "Fri Apr 08 04:47:27 UTC 2011",
 "updated_at": "Fri Apr 08 04:47:27 UTC 2011",
 "overview": "\u003Cp\u003EAstex is a UK-based biotechnology company that discovers and develops novel small molecule therapeutics. Using its pioneering fragment-based drug discovery platform, Pyramid\u00e2\u201e\u00a2, Astex has built a pipeline of molecularly-targeted oncology drugs, of which three are currently being tested in clinical trials with others in discovery and pre-clinical development.\u003C/p\u003E\n\n\u003Cp\u003EIn addition to its proprietary research programs, Astex\u00e2\u20ac\u2122s productivity in lead discovery has been endorsed through numerous partnerships with major pharmaceutical companies, including AstraZeneca, GlaxoSmithKline, Johnson \u0026amp; Johnson and Novartis. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       51],
      "assets/images/resized/0012/9731/129731v1-max-150x150.jpg"],
     [[200,
       69],
      "assets/images/resized/0012/9731/129731v1-max-250x250.jpg"],
     [[200,
       69],
      "assets/images/resized/0012/9731/129731v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "CEO",
    "person":
     {"first_name": "Harren",
      "last_name": "Jhoti",
      "permalink": "harren-jhoti",
      "image": null}},
   {"is_past": false,
    "title": "SAB member",
    "person":
     {"first_name": "Mark",
      "last_name": "Murcko",
      "permalink": "mark-murcko",
      "image":
       {"available_sizes":
         [[[150,
            135],
           "assets/images/resized/0027/4281/274281v1-max-150x150.jpg"],
          [[250,
            225],
           "assets/images/resized/0027/4281/274281v1-max-250x250.jpg"],
          [[450,
            405],
           "assets/images/resized/0027/4281/274281v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition":
  {"price_amount": 55000000.0,
   "price_currency_code": "USD",
   "term_code": "cash_and_stock",
   "source_url": "http://www.fiercebiotech.com/story/supergen-snags-uks-astex-55m-ma-deal/2011-04-07?utm_medium=rss\u0026utm_source=rss",
   "source_description": "SuperGen snags UK's Astex in a $55M M\u0026A deal",
   "acquired_year": 2011,
   "acquired_month": 4,
   "acquired_day": 7,
   "acquiring_company":
    {"name": "SuperGen",
     "permalink": "supergen",
     "image":
      {"available_sizes":
        [[[150,
           60],
          "assets/images/resized/0007/2509/72509v1-max-150x150.png"],
         [[180,
           72],
          "assets/images/resized/0007/2509/72509v1-max-250x250.png"],
         [[180,
           72],
          "assets/images/resized/0007/2509/72509v1-max-450x450.png"]],
       "attribution": null}}},
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "436 Cambridge Science Park",
    "address2": "Milton Road",
    "zip_code": "CB4 0QA",
    "city": "Cambridge",
    "state_code": null,
    "country_code": "GBR",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}